Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
NCT ID: NCT02269995
Last Updated: 2018-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2014-03-06
2015-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Factors considered to have effect to safety and effectiveness
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Surveillance of Hepatocellular Carcinoma
NCT05286099
Added Value of Gadoxetic Acid-enhanced Liver MRI
NCT03045419
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
NCT05359939
Evaluation of Patients With Liver Disease
NCT00001971
Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
NCT03129685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
E7040
E7040
E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E7040
E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Locations, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jpn J Intervent Radiol. 2017;32:136-141.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DCB01S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.